JAK1 and hepatocellular carcinoma: In vitro studies demonstrated that AZD1480, an ATP-competitive inhibitor of JAK1 (Janus kinase 1) and JAK2 (Janus kinase 2), could inhibit HAV genotype III replication in human hepatoma cells.